Clinical remission maintained and improved over time in patients with severe asthma treated with omalizumab

References

• 2023 GINA Main Report. Global Initiative for Asthma https://ginasthma.org/2023-gina-main-report/ (accessed January 22, 2024).
   Google Scholar
• Schoettler N, Strek ME. Recent advances in severe asthma: from phenotypes to personalized medicine. Chest 2020;157(3):516–528. doi:10.1016/j.chest.2019.10.009.
   PubMed Web of Science ®Google Scholar
• Bousquet J, Humbert M, Gibson PG, Kostikas K, Jaumont X, Pfister P, Nissen F. Real-world effectiveness of omalizumab in severe allergic asthma: a meta-analysis of observational studies. J Allergy Clin Immunol Pract 2021;9(7):2702–2714. doi:10.1016/j.jaip.2021.01.011.
   PubMed Web of Science ®Google Scholar
• Humbert M, Taillé C, Mala L, Le Gros V, Just J, Molimard M. Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study. Eur Respir J 2018;51(5):1702523. doi:10.1183/13993003.02523-2017.
   PubMed Web of Science ®Google Scholar
• Menzies-Gow A, Bafadhel M, Busse WW, Casale TB, Kocks JWH, Pavord ID, Szefler SJ, Woodruff PG, de Giorgio-Miller A, Trudo F, et al. An expert consensus framework for asthma remission as a treatment goal. J Allergy Clin Immunol 2020;145(3):757–765. doi:10.1016/j.jaci.2019.12.006.
   PubMed Web of Science ®Google Scholar
• Menzies-Gow A, Hoyte FL, Price DB, Cohen D, Barker P, Kreindler J, Jison M, Brooks CL, Papeleu P, Katial R, et al. Clinical remission in severe asthma: a pooled post hoc analysis of the patient journey with benralizumab. Adv Ther 2022;39(5):2065–2084. doi:10.1007/s12325-022-02098-1.
   PubMed Web of Science ®Google Scholar
• Thomas D, McDonald VM, Stevens S, Harvey ES, Baraket M, Bardin P, Bowden JJ, Bowler S, Chien J, Chung LP, et al. Biologics (mepolizumab and omalizumab) induced remission in severe asthma patients. Allergy 2024;79(2):384–392. doi:10.1111/all.15867.
   PubMed Web of Science ®Google Scholar
• Valverde-Monge M, Sánchez-Carrasco P, Betancor D, Barroso B, Rodrigo-Muñoz JM, Mahillo-Fernández I, et al. Comparison of long-term response and remission to omalizumab and anti-IL-5/IL-5R using different criteria in a real-life cohort of severe asthma patients. Arch Bronconeumol. 2024;60(1):23–32. doi:10.1016/j.arbres.2023.11.011.
   PubMed Web of Science ®Google Scholar
• Oishi K, Hamada K, Murata Y, Matsuda K, Ohata S, Yamaji Y, Asami-Noyama M, Edakuni N, Kakugawa T, Hirano T, et al. A real-world study of achievement rate and predictive factors of clinical and deep remission to biologics in patients with severe asthma. J Clin Med 2023;12(8):2900. doi:10.3390/jcm12082900.
   PubMed Web of Science ®Google Scholar
• Numata T, Araya J, Okuda K, Miyagawa H, Minagawa S, Ishikawa T, Hara H, Kuwano K. Long-term efficacy and clinical remission after benralizumab treatment in patients with severe eosinophilic asthma: a retrospective study. J Asthma Allergy 2022;15:1731–1741. doi:10.2147/JAA.S391807.
   PubMed Web of Science ®Google Scholar
• Moermans C, Brion C, Bock G, Graff S, Gerday S, Nekoee H, Poulet C, Bricmont N, Henket M, Paulus V, et al. Sputum type 2 markers could predict remission in severe asthma treated with anti-IL-5. Chest 2023;163(6):1368–1379. doi:10.1016/j.chest.2023.01.037.
   PubMed Web of Science ®Google Scholar
• Pavord I, Gardiner F, Heaney LG, Domingo C, Price RG, Pullan A, Oppenheimer J, Brusselle G, Nagase H, Chupp G, et al. Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: analysis of the REDES study. Front Immunol 2023;14:1150162. doi:10.3389/fimmu.2023.1150162.
   PubMed Web of Science ®Google Scholar
• Milger K, Suhling H, Skowasch D, Holtdirk A, Kneidinger N, Behr J, Timmermann H, Schulz C, Schmidt O, Ehmann R, et al. Response to biologics and clinical remission in the adult german asthma net severe asthma registry cohort. J Allergy Clin Immunol Pract 2023;11(9):2701–2712.e2. doi:10.1016/j.jaip.2023.05.047.
   PubMed Web of Science ®Google Scholar
• Padilla-Galo A, Moya Carmona I, Ausín P, Carazo Fernández L, García-Moguel I, Velasco-Garrido JL, Andújar-Espinosa R, Casas-Maldonado F, Martínez-Moragón E, Martínez Rivera C, et al. Achieving clinical outcomes with benralizumab in severe eosinophilic asthma patients in a real-world setting: ORBE II study. Respir Res 2023;24(1):235. doi:10.1186/s12931-023-02539-7.
   PubMed Web of Science ®Google Scholar
• Sposato B, Bianchi F, Ricci A, Scalese M. Clinical asthma remission obtained with biologics in real life: patients’ prevalence and characteristics. J Pers Med 2023;13(6):1020. doi:10.3390/jpm13061020.
   PubMed Web of Science ®Google Scholar
• Maglio A, Vitale C, Pelaia C, D’Amato M, Ciampo L, Sferra E, Molino A, Pelaia G, Vatrella A. Severe asthma remissions ınduced by biologics targeting IL5/IL5r: results from a multicenter real-life study. Int J Mol Sci 2023;24(3):2455. doi:10.3390/ijms24032455.
   PubMed Web of Science ®Google Scholar
• McDowell PJ, McDowell R, Busby J, Eastwood MC, Patel PH, Jackson DJ, Mansur A, Patel M, Burhan H, Doe S, et al. Clinical remission in severe asthma with biologic therapy: an analysis from the UK Severe Asthma Registry. Eur Respir J 2023;62(6):2300819. doi:10.1183/13993003.00819-2023.
   PubMed Web of Science ®Google Scholar
• Breslavsky A, Al Qaied A, Tsenter P, Mukaseev N, Alamor M, Cohen-Hagai K, Wand O. Comparison of clinical remission criteria for severe asthma patients receiving biologic therapy. Respir Med 2024;222:107528. doi:10.1016/j.rmed.2024.107528.
   PubMedGoogle Scholar
• Yeşilkaya S, Aksu K, Tuğçe Vural Solak G, Akkale O, Telli O, Tuğlu HC, Köycü Buhari G, Bahçecioğlu SN, Demir S. Variables predicting clinical remission among adults with severe asthma treated with biologic agents. Eur Ann Allergy Clin Immunol 2023. doi:10.23822/EurAnnACI.1764-1489.318.
   PubMedGoogle Scholar